Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ehjcr/ytaa188 http://scihub22266oqcxt.onion/10.1093/ehjcr/ytaa188 33089052!7454490!33089052     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33089052&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+Heart+J+Case+Rep 2020 ; 4 (FI1): 1-6 Nephropedia Template TP {{tp|p=33089052|t=2020. Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report |pdf=|usr=}}{{33089052}} gab.com Text Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report JO: Eur Heart J Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33089052 #FOAvip BACKGROUND: SARS-CoV-2 is known to induce a cytokine storm, a hyperinflammatory state driven by up-regulation of interleukin 6 (IL-6) and immunomodulatory chemokines that may result in acute heart failure. CASE SUMMARY: A 65-year-old woman with confirmed SARS-CoV-2 developed shock with multiorgan system failure, including acute biventricular heart failure, 2 weeks after the initial onset of fever, cough, and shortness of breath. The patient experienced myocardial recovery within 48 h after administration of tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, and multiple supportive vasoactive medications. DISCUSSION: The differential diagnosis of acute heart failure in critically ill patients with COVID-19 infection is broad, including sepsis-induced cardiomyopathy, Takotsubo syndrome, viral lymphocytic myocarditis, and acute coronary syndrome. Immunomodulatory treatment with tocilizumab may benefit patients who develop cardiogenic shock associated with SARS-CoV-2-induced cytokine storm. Twit Text FOAVip Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report ????Eur Heart J Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33089052 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33089052 #FOAvip English Wikipedia <ref>{{Cite pmid|33089052}}</ref> Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report #MMPMID33089052 Chitturi KR; Thacker S; Al-Saadi MA; Kassi M Eur Heart J Case Rep 2020[Oct]; 4 (FI1): 1-6 PMID33089052show ga BACKGROUND: SARS-CoV-2 is known to induce a cytokine storm, a hyperinflammatory state driven by up-regulation of interleukin 6 (IL-6) and immunomodulatory chemokines that may result in acute heart failure. CASE SUMMARY: A 65-year-old woman with confirmed SARS-CoV-2 developed shock with multiorgan system failure, including acute biventricular heart failure, 2 weeks after the initial onset of fever, cough, and shortness of breath. The patient experienced myocardial recovery within 48 h after administration of tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, and multiple supportive vasoactive medications. DISCUSSION: The differential diagnosis of acute heart failure in critically ill patients with COVID-19 infection is broad, including sepsis-induced cardiomyopathy, Takotsubo syndrome, viral lymphocytic myocarditis, and acute coronary syndrome. Immunomodulatory treatment with tocilizumab may benefit patients who develop cardiogenic shock associated with SARS-CoV-2-induced cytokine storm. ?Successful treatment of acute heart failure in COVID-19-induced cytoki(epmc).pdf DeepDyve Pubget Overpricing